ライフサイエンスコーパス: NaI

1 NF-kappaB or NF-kappaB activation inhibitor (NAI).

2 to investigate naturally acquired immunity (NAI).

3 vels of functional NA-inhibiting antibodies (NAI).

4 autism relative to non-autistic individuals (NAI).

5 es (a lithium salt or a sodium salt, such as NaI).

6 ose within 6 hours of hospitalization (early NAI).

7 susceptibility to neuraminidase inhibitors (NAIs).

8 ucleotide Analogue Interference Suppression (NAIS).

9 resistant to neuraminidase (NA) inhibitors (NAIs).

10 y prior depletion of intracellular free Na+ (Nai+).

11 inhibited by the presence of the respective NAI.

12 malaria model incorporating vaccination and NAI.

13 oid carcinoma after administration of (124)I-NaI.

14 a(2)SO(4) and an increasing concentration of NaI.

15 an individual in a malaria-endemic area with NAI.

16 tions that are present in our N2 NA panel on NAI.

17 lling of the clonal landscape in response to NAI.

18 itutions known to impart resistance to other NAIs.

19 y share common resistance markers with these NAIs.

20 ing influenza A viruses in susceptibility to NAIs.

21 influenza viruses tested were susceptible to NAIs.

22 utions yielded susceptibility to one or more NAIs.

23 our study may help to optimize the design of NAIs.

24 ve not been reported to confer resistance to NAIs.

25 spective purified substrates, we showed that NAI-107 forms complexes with bactoprenol-pyrophosphate-c

26 The lantibiotic NAI-107 is active against Gram-positive bacteria includi

27 w membrane depolarization was observed after NAI-107 treatment, which could contribute to killing of

28 and stress), 123I-/124I-/131I-OIH, 123I/131I-NaI, 125I-iothalamate, 111In-DTPA and 89Sr-SrCl.

29 d 4 deaths in the 116 patients not receiving NAI (3.4%).

30 total of 212 children were studied: 46 with NAIS, 34 with APPIS, 55 with PVI, and 77 controls (male,

31 (3) (1), mediated by TBAT (2-12 mol %) or by NaI (5-20 mol %), has been investigated by in situ/stopp

32 inhibitory concentrations against all tested NAIs (827-, 25-, 286-, and 702-fold for zanamivir, oselt

33 ntitatively profiled by ESI-MS analysis with NaI additive.

34 on of iodine species such as HIO and I2 from NaI aerosolized solutions exposed to 50 ppbv O3 can occu

35 Halide exchange with NaBr or NaI affords the corresponding bromide and iodide congene

36 d to 18 deaths in the 399 patients receiving NAI after 6 hours (4.5%) and 4 deaths in the 116 patient

37 so rapidly determining the effectiveness of NAIs against new viral strains is vital for deciding how

38 Seroconversion to NAI alone was higher among children aged <5 years vs tho

39 icipants, of whom 100 (31%) seroconverted to NAI alone.

40 associated with contact ion-pair binding of NaI (alpha = 1300, DeltaGalpha = -18 kJ mol(-1)) and NaC

41 of (125)I-DCIBzL, 111 MBq (3 mCi) of (125)I-NaI, an equivalent amount of nonradiolabeled DCIBzL, or

42 ene expression patterns intermediate between NAI and EFFE T cells.

43 The addition of NaI and NaSCN altered the properties of visco-elastic ma

44 ons were susceptible to at least one or more NAIs and showed for a small selection that in vitro data

45 ) exhibited reduced inhibition by all of the NAIs and two variants (E119D and E119D-H274Y) retained t

46 (TBAT) or quasi-stochastic autoacceleration (NaI) and cogenerating perfluoroalkene side products.

47 za antivirals, the neuraminidase inhibitors (NAIs) and the adamantanes, are well characterized, as ar

48 patients had MS; 18, MG; 10, GBS; 5, another NAID; and 57, PD.

49 However, neuraminidase-inhibiting (NAi) antibodies can reduce viral spread and may be of pa

50 ignificant rise of functional NA inhibition (NAI) antibodies to N1 of 2.3.4.4b A(H5N1), and group 1 H

51 Analyses suggested an independent role for NAI antibody in protection, which was similar in the IIV

52 While NAI antibody is not produced to a large extent in respon

53 re we demonstrate the effective induction of NAi antibody titers after H5N1 vaccination in humans.

54 Neuraminidase inhibitor (NAI) antiviral drugs can shorten the duration of uncompl

55 The conserved residues that interact with NAIs are under selective pressure, but only a few have b

56 Neuraminidase inhibitors (NAIs) are antivirals designed to target conserved residu

57 Neuraminidase inhibitors (NAIs) are stockpiled internationally for extended use in

58 Currently, neuraminidase (NA) inhibitors (NAIs) are the first choice for influenza prevention and

59 The neuraminidase (NA) inhibitors (NAIs) are the frontline anti-influenza drugs and are the

60 Although neuraminidase (NA) inhibitors (NAIs) are the only class of antiviral drugs available fo

61 Neuraminidase (NA) inhibitors (NAIs) are the only class of drugs available to treat inf

62 Neuraminidase inhibitors (NAIs) are the only effective therapy for influenza, but

63 Neuraminidase (NA) inhibitors (NAIs) are the primary option for treatment, but informat

64 lassified neonatal arterial ischemic stroke (NAIS), arterial presumed perinatal ischemic stroke (APPI

65 o)ethylene as the reductant uses FeBr(2) and NaI as additives to achieve selective cross-coupling.

66 positive detection mode using sodium iodide (NaI) as an additive.

67 ng readily available sodium salts (NaCl/NaBr/NaI) as halogen source and K(2)S(2)O(8) (or) oxone as pr

68 olyzes ATP to export three intracellular Na (Nai) as it imports two extracellular K (Ko) across anima

69 ility of vaccines, neuraminidase inhibitors (NAIs), as the only available class of drugs for AIVs in

70 The NAI assay detected a vaccine response in 37% of IIV reci

71 MN assay titers were highly correlated, but NAI assay titers exhibited less of a correlation.

72 In IIV recipients, as NAI assay titers rose, the frequency of infection fell,

73 dized lectin-based neuraminidase inhibition (NAI) assay.

74 olutions containing NaCl, NaBr, NH(4)Cl, and NaI at concentrations between 10(-6) and 10(-1) M were s

75 6, and D151) that directly interact with the NAIs but have not been reported to confer resistance to

76 hat have a major impact on susceptibility to NAI by immune sera are in proximity of the catalytic sit

77 a signal from the intracellular compartment (Nai) compared with an external standard (monitored by Na

78 owever, analysis of this model revealed that NAI, compounded by a subpopulation with only partial pro

79 However, upon further increase in the NaI concentration, this weakly hydrated anion is forced

80 l titers when treated with their susceptible NAIs, confirming the in vitro susceptibility of these su

81 tions containing Na(2)SO(4), NaCl, NaBr, and NaI containing solutions, and H(2)O(2) was monitored as

82 using pairs of spherical ions (NaCl > NaBr > NaI) correlates to experimental observations (NaI > NaCl

83 were examined in the presence of 3 and 25 mM NaI, corresponding to I(-)-activated and I(-)-inhibited

84 r certain substrates without the addition of NaI, could be used in loadings of < or =1 mol %.

85 ead gamma camera equipped with 2.54-cm-thick NaI crystals operating in coincidence mode.

86 Chemoprophylaxis with NAIs decreased the frequency of symptomatic influenza (r

87 e patient-level factors that determine early NAI delivery in hospitalized patients.

88 Activity was monitored by using an NaI detector.

89 TSM)] pharmacokinetics were determined using NaI detectors, with intracellular pH and cardiac energet

90 films, the delayed fluorescence component of NAI-DMAC emission was extended to longer time scales and

91 ion to explore the possibility of extracting NAI drug efficacy using only the observed viral titer de

92 We isolated NAI, EFFE, and MEM CD8(+) T cell subsets from human peri

93 tified 156 genes that strongly differentiate NAI, EFFE, and MEM CD8(+) T cells; these genes provide p

94 overall survival [OS]), and safety outcomes (NAID exacerbation, irAEs) were collected.

95 ed ex vivo from cervical lymph node cells of NaI-fed or control mice, suggesting that the iodide-rich

96 in intensive care units (ICUs) treated with NAIs for influenza A(H1N1)pdm09 (pH1N1).

97 8-h period, and whole blood was counted on a NaI gamma-counter.

98 ifluorocarbene (generated from PhHgCF(3) and NaI) gave diastereomeric mixtures of the 2,2-difluorospi

99 difluorocarbene [generated from (CF3)2Hg and NaI] gave a diastereomeric mixture of the 3',4'-difluoro

100 No patients died in the early NAI group, compared to 18 deaths in the 399 patients rec

101 ponse rate, PFS, or OS were observed between NAID groups.

102 aI) correlates to experimental observations (NaI > NaClO4).

103 ced in the following order: NaSCN > NaClO4 > NaI > NaNO3 approximately NaBr > NaCl > pure water appro

104 NAI had no effect.

105 For LAIV recipients, the NAI, HAI, and MN assays detected responses in 6%, 21%, a

106 Neuraminidase inhibitors (NAIs) have been widely used to control influenza virus i

107 e less effort in vaccination as the level of NAI in a population, and as disease prevalence, increase

108 rin pairs per volume of MOF that bind PC and NAI in such a way that they are primed to form the requi

109 bulin autoantibodies when they receive 0.05% NaI in their drinking water beginning at 8 wk of age.

110 NOD.H-2h4 mice given NaI in their drinking water develop iodine-accelerated s

111 utoimmune thyroiditis (SAT) when given 0.05% NaI in their drinking water, whereas B cell-deficient NO

112 IFN-gamma(-/-)NOD.H-2h4 mice given 0.05% NaI in their water develop severe thyroid epithelial cel

113 Lessons learned from NAID in cardiovascular disease could ultimately translat

114 Endeavours to tackle NAID in heart failure have yielded mixed results, exposi

115 e effectiveness of neuraminidase inhibitors (NAIs) in humans infected with influenza A(H7N9) viruses

116 e effectiveness of neuraminidase inhibitors (NAIs) in reducing mortality when given to hospitalized p

117 untapped opportunities in the management of NAID, including the refinement of current approaches and

118 ically relevant nicotine aerosol inhalation (NAI) induced transient reduction and irregular fluctuati

119 rehensive understanding of the mechanisms of NAI-induced inhibition of influenza virus and help lead

120 ates uterine blood vessels, counteracted the NAI-induced reduction in uterine blood flow.

121 y acquired immunity (NAI) to severe malaria; NAI is caused by repeated exposure to infectious bites a

122 Because NAI is derived from mechanistic models, it is both easie

123 he HDH reactivity of HACs in the presence of NaI is rather low.

124 ) mice develop severe TEC H/P, and 2-3 wk of NaI is sufficient for optimal development of severe TEC

125 Non-anaemic iron deficiency (NAID) is a strategic target in cardiovascular medicine b

126 tivirals, the neuraminidase (NA) inhibitors (NAIs), is a public health concern.

127 ation is eliminated using the sodium iodide (NaI) isolation method and that the level of oxo8dG in nu

128 dehyde, depending on whether one uses either NaI/K(2)CO(3) or LiBr/K(2)CO(3).

129 th TFAA or chloroformates in the presence of NaI leads to the efficient generation of alkyl iodides,

130 with benzyl chloroformate in the presence of NaI led to iodohydrin intermediates which gave spiroepox

131 -substituted 2-aminobenzimidazoles through a NaI-mediated desulfurization-cyclization process is repo

132 It allows rationalization of why the NaI-mediated process is more effective for less-reactive

133 cation of the recently introduced chaotropic NaI method, reducing our estimate of the level of steady

134 ance and continued surveillance of potential NAI multidrug-resistant influenza virus variants, as wel

135 cells are treated with the icSHAPE chemical NAI-N3 followed by selective chemical enrichment of NAI-

136 followed by selective chemical enrichment of NAI-N3-modified RNA, which provides an improved signal-t

137 define the nonsense error adaptation index (NAI) of the allele or a contiguous subset thereof.

138 analyzed by primer extension (SHAPE) reagent NAI on naked RNA under in vitro conditions, but it signi

139 The effect of changes of Nai+ on Nao+-sensitive transient current was investigate

140 The effects of lowering Nai+ on pre-steady-state transient current can be accoun

141 e extracted from the Paracoccus membranes by NaI or alkaline treatment, unlike the peripheral subunit

142 e extracted from the Paracoccus membranes by NaI or alkaline treatment, which is consistent with the

143 terface when increasing the concentration of NaI or NaBr from 0.010 to 100 muM.

144 Treatments with chaotropic reagents (urea, NaI, or NaBr) or with alkaline buffer (pH 10-12) resulte

145 The NAI oseltamivir (5, 20, or 80 mg/kg/day) was administere

146 utation (H274Y) conferring resistance to the NAI oseltamivir emerged worldwide in the A/H1N1 virus su

147 ed resistant variants in the presence of the NAIs oseltamivir carboxylate and zanamivir in MDCK cells

148 ltidrug resistance to the currently approved NAIs oseltamivir, zanamivir, and peramivir by assessing

149 in N6, and 4 in N8) conferred resistance to NAIs (oseltamivir carboxylate, zanamivir, or peramivir)

150 utions associated with reduced inhibition by NAIs (oseltamivir, zanamivir, and peramivir): (i) novel

151 enza NA enzyme active site as those of other NAIs, oseltamivir (OS), zanamivir (ZAN), and peramivir,

152 pregnancy were more likely to receive early NAI (P = .01, vs. P < .001 in those without these condit

153 d patients were less likely to receive early NAI (P = .04).

154 ical structures of neuraminidase inhibitors (NAIs) possess similarities, but slight differences can r

155 ves in situ generation of N-acyliminium ion (NAI) precursor under catalyst and solvent-free condition

156 al planar gamma-camera images and whole-body NaI probe counts were obtained to estimate (131)I-antibo

157 aotropic technique of DNA isolation by using NaI produced the lowest and least variable oxo8dG values

158 lving Rh-catalyzed aziridination followed by NaI-promoted rearrangement to an isomeric cyclic sulfami

159 Naturally acquired immunity (NAI) protects against malaria in adults residing in infe

160 I compare to different alkali metal iodides: NaI, RbI, CsI; also investigation of different potassium

161 rse effects were not increased overall among NAI recipients (RR, 1.01 [CI, 0.94 to 1.08]; RD, 0.1 per

162 ention for AIV-infected patients, studies on NAI resistance among AIVs have been limited, and markers

163 NA amino acid substitutions associated with NAI resistance among influenza viruses of N3, N7, and N9

164 sential to identify the molecular markers of NAI resistance among specific NA subtypes of avian influ

165 by a S31N mutation in the matrix gene, while NAI resistance can result from a number of mutations in

166 Although various mutations associated with NAI resistance have been identified, the amino acid subs

167 To screen for substitutions conferring NAI resistance in AIVs of N4, N5, N6, and N8 NA subtypes

168 ort profiles of NA substitutions that confer NAI resistance in AIVs of the N4, N5, N6, and N8 NA subt

169 ating antiviral susceptibility monitoring of NAI resistance in AIVs.IMPORTANCE The frequency of human

170 he molecular changes in NA that could confer NAI resistance in avian viruses grown in immortalized mo

171 gence of a single NA mutation conferring pan-NAI resistance in the clinical setting reinforces the pr

172 We identified 16 NA substitutions conferring NAI resistance in the tested AIV subtypes; some are nove

173 strate that each NA subtype possesses unique NAI resistance markers, and knowledge of these substitut

174 of NA subtypes improves the understanding of NAI resistance mechanisms.

175 For NAI resistance mutation detection, we used a mutation-sp

176 Previously, we identified unique NAI resistance substitutions in AIVs of the N3, N7, and

177 Substitutions conferring NAI resistance were mainly categorized as either novel N

178 everse genetics (rg) that is associated with NAI resistance.

179 (RT-qPCR) for influenza type and subtype and NAI resistance.

180 ed, sequenced, and phenotypically tested for NAI resistance.

181 ed in 2008 to study neuraminidase inhibitor (NAI) resistance and clinical outcome.

182 Since most studies have focused on NAI-resistance in human influenza viruses, we investigat

183 whether the in vitro susceptibility of multi-NAI-resistant AIVs is associated with in vivo susceptibi

184 The fitness of NAI-resistant influenza B viruses has not been widely st

185 o use NHBE cells to determine the fitness of NAI-resistant influenza B viruses.

186 ne the replicative capacities and fitness of NAI-resistant influenza B viruses.

187 NAI-resistant substitutions in NA subtypes other than N1

188 We identified not only numerous NAI-resistant substitutions previously reported in other

189 nd B virus infections, so the development of NAI-resistant viruses with superior fitness is a public

190 ss of the risk assessment for the fitness of NAIs-resistant seasonal H1N1 and H3N2, pandemic 2009 H1N

191 d HA, a single vaccine dose induced a strong NAi response that was not significantly boosted by a sec

192 %, whereas the inhibition of NF-kappaB using NAI resulted in a decrease in females from 45 to 20%.

193 Influenza infection (either HAI or NAI seroconversion) was found in 321 (35% [95% confidenc

194 complexes with a different concentration of NaI showed that the mutations decreased affinity between

195 seltamivir, an oral neuraminidase inhibitor (NAI), so rapidly determining the effectiveness of NAIs a

196 d from the sediment based on density using a NaI solution (1.6 g/mL).

197 Without NaI supplementation, 50% of 5- to 6-mo-old CD28(-/-)IFN-

198 mma(-/-) NOD.H-2h4 mice given sodium iodide (NaI)-supplemented water develop a slow onset autoimmune

199 oseltamivir-treated patient were tested for NAI susceptibility in vitro; their replicative fitness w

200 ore, the association of in vitro and in vivo NAI susceptibility indicates that our models are useful

201 t our models are useful tools for monitoring NAI susceptibility of AIVs.IMPORTANCE The chemical struc

202 We coinfected NHBE cells with NAI-susceptible and -resistant viruses and used next-gen

203 g-E119A was easily masked by the presence of NAI-susceptible virus.

204 e fitness greater than that of the wild-type NAI-susceptible virus.

205 A high and uniform expression of the NaI symporter in malignant thyroid cells results in tumo

206 oxidants produced by a cell-free H2O2-FeSO4-NaI system than were controls.

207 rmance, followed by the large-area dedicated NaI system, and hybrid PET gamma cameras.

208 can be generated using the tetrabromoxylene/NaI system, the 1,3-diphenylisobenzofuran/BF(3) system,

209 CZT detector was 76% that of the equivalent NaI system.

210 n-rich bicyclo[1.1.0]butanes by the CF(3)TMS/NaI system.

211 nominal counting rates were obtained for the NaI systems, and the bismuth germanate (BGO) systems wer

212 As such, conditions under which NAI T cells are activated may determine the magnitude of

213 Furthermore, whether NAI T cells serially differentiate into EFFE and then ME

214 l basis underlying differentiation of naive (NAI) T cells into effector (EFFE) and memory (MEM) cells

215 emonstrated reduced inhibition by all of the NAIs tested in both the backbone of the 2009 H1N1 pandem

216 utions that conferred resistance to all four NAIs tested.

217 We found using NaI that the ratio of oxo8dG/10(5 )deoxyguanosine (dG) i

218 ew studies have assessed the impact of early NAI therapy on clinical outcomes or the patient-level fa

219 Over multiple influenza seasons, early NAI therapy was associated with shorter LOS in patients

220 We analyzed the association of early NAI therapy with hospital lengths of stay (LOS) and in-h

221 evel factors that were associated with early NAI therapy.

222 Of those, 582 (83.4%) received NAI therapy; however, only 26.0% received the first dose

223 Using difluorocarbene, generated from TMSCF3/NaI, these spirocycles were produced in yields up to 97%

224 also showed reduced inhibition by all of the NAIs, though their overall viral fitness was impaired in

225 hibition (HAI) and neuraminidase inhibition (NAI) titer decline in the absence of infection were esti

226 HAI and NAI titers decreased slowly over 18 months; overall, a 2

227 NAI titers predicted all outcomes of interest and may ex

228 I titers were similar between the sexes, but NAI titers were higher in males than females at 4 weeks

229 c regression models showed that prechallenge NAI titers, but not HAI titers or sex hormone levels, we

230 nhibition (HAI) or neuraminidase inhibition (NAI) titers for seroconversion.

231 tion (HAI) titers, neuraminidase inhibition (NAI) titers, and outcomes after challenge were compared.

232 and 9 wk after injection using spectrometric NaI(Tl) and HPGe detectors, and imaging between 5 and 10

233 The camera has a 10 x 10 x 1 cm NaI(Tl) crystal with four photomultipliers.

234 T scanners, is unique in the use of 6 curved NaI(Tl) detectors (2.54 cm thick).

235 Using a NaI(Tl) scintillation detector designed to operate in el

236 context of standard halo model with the same NaI(Tl) target for various interaction hypotheses.

237 f a commercial inorganic X-ray scintillator (NaI:Tl).

238 N1 strain, these mice demonstrated a reduced NAI to the challenged virus.

239 ty for acyl transfer from N-acetylimidazole (NAI) to different pyridylcarbinol (PC) regioisomers (2-P

240 high levels of naturally acquired immunity (NAI) to severe malaria; NAI is caused by repeated exposu

241 uorescent probe, naltrexamine-acylimidazole (NAI), to label opioid receptors based on a chemical appr

242 In cells depleted of Nai+ to inhibit the triggering of sarcoplasmic reticulum

243 NaI-treated and mutant photosystem I complexes were used

244 fitness of H7N9 NA variants that emerged in NAI-treated patients.

245 er research is needed about whether starting NAI treatment >5 days after symptom onset may also conve

246 ed odds of hospital admission compared to no NAI treatment (adjusted odds ratio, 0.24; 95% confidence

247 d a nonsignificant reduction associated with NAI treatment (at any time) versus none (OR, 0.72 [95% C

248 NAI treatment (at any time) versus none was associated w

249 ision tumour', which was only detected after NAI treatment of baseline ER+ disease.

250 NAI treatment of critically ill pH1N1 patients improves

251 gression modeling to determine the effect of NAI treatment on hospitalization.

252 We investigated the impact of outpatient NAI treatment on subsequent hospitalization in patients

253 We adjusted for NAI treatment propensity and preadmission antibiotic use

254 adjustment for preadmission antibiotics and NAI treatment propensity, preadmission NAI treatment was

255 luenza A(H1N1) pandemic, early initiation of NAI treatment reduced the likelihood of severe outcomes

256 spitalization, outpatient or community-based NAI treatment significantly reduced the likelihood of re

257 e median time from symptom onset to starting NAI treatment was 4 days (range, 0-52 days).

258 s and NAI treatment propensity, preadmission NAI treatment was associated with decreased odds of hosp

259 NAI treatment was associated with survival: 107 of 183 u

260 5.8%) received outpatient or community-based NAI treatment, 928 of 2395 (38.8%) with available data h

261 h information available, 1676 (90%) received NAI treatment, and 183 (10%) did not.

262 atients with severe influenza should receive NAI treatment.

263 The impact of neuraminidase inhibitor (NAI) treatment on clinical outcomes of public health imp

264 4 months of neoadjuvant aromatase inhibitor (NAI) treatment.

265 or two water molecules are able to detach an NaI unit from the Na(3)I(2)(+) cluster.

266 fference in the energies required to lose an NaI unit from these two species.

267 ent also confirms that the loss of a neutral NaI unit, instead of an Na(+) ion, occurs during the dis

268 the dissolution processes, loss of a neutral NaI unit, occurs when six or more water molecules have b

269 Conceptually, the NAI value of an allele is a relative measure of its elev

270 To illustrate its utility, we calculate NAI values for the entire coding sequence and across a s

271 Nai;ve animals recovering from ischemia took longer to r

272 unity, invertebrate hosts are believed to be nai;ve at each new encounter with pathogens.

273 te in Drosophila that Clock misexpression in nai;ve brain regions induces circadian gene expression.

274 In quiescent nai;ve lymphocytes, antigen recognition with appropriate

275 Cohabitation of sexually nai;ve male and female prairie voles (Microtus ochrogast

276 Nai;ve myogenic cells migrate from the somites into the

277 residues in framework stabilization, we used nai;ve phage-displayed libraries, combinatorial alanine-

278 Sexually nai;ve prepubertal and adult male hamsters were exposed

279 sented by mature dendritic cells in the DLN, nai;ve T cells can respond to self antigens or tumor ant

280 Rather, the conditions under which nai;ve T cells encounter antigen in the DLN can result i

281 Nai;ve T cells in the draining lymph node (DLN) do not i

282 sectional study, three different age sets of nai;ve TgCRND8 and non-Tg mice were tested: 10-12, 12-14

283 ant preconcentration and alignment of PC and NAI via coordination to framework porphyrin sites (orien

284 Early NAI was associated with shorter hospital LOS (P < .001).

285 and ATP-induced processing were blocked when NaI was substituted for NaCl within the medium; substitu

286 tissue after 2 Gy of gamma-irradiation when NaI was used to isolate DNA.

287 Susceptibility of N9 viruses to NAIs was determined in a fluorescence-based assay.

288 Susceptibility to NA inhibitors (NAIs) was evaluated with a fluorometric assay using the

289 As Nai+ was decreased, the amount of charge measured and it

290 AT), all TGF-beta transgenic (Tg) mice given NaI water for 2-7 mo developed thyroid lesions character

291 ctions of anti-CD25 developed SAT 8 wk after NaI water.

292 i.e., starting 4 wk after administration of NaI water.

293 ccines will perform in regions with existing NAI, we developed a simple malaria model incorporating v

294 conditions, but it significantly outperforms NAI when probing RNA structure in vivo, particularly in

295 the labeling of arylstannanes using [(125)I]NaI, where products were isolated in high specific activ

296 tions reduced the susceptibility to all four NAIs, whereas the remaining 26 substitutions yielded sus

297 changes conferring reduced susceptibility to NAIs, which are subtype specific.

298 A vaccine that replicates NAI will effectively prevent disease.

299 a long-acting neuraminidase (NA) inhibitor (NAI) with a similar binding profile in the influenza NA

300 mple combination of water and sodium iodide (NaI) with chlorotrimethylsilane (TMSCl), promotion of a